Provention Bio receives FDA nod for TzieldTzield is the first and only treatment indicated to delay the onset of stage 3 type 1 diabetes in adult and pediatric patients aged 8 years old and older with stage 2 type 1 diabetes. Medicines360 obtains FDA nod for extended duration of use of LilettaWith this FDA approval, Liletta has one of the longest approved durations of use for a hormonal intrauterine device in the United States. Lilly to begin rollout of Tempo personalized diabetes management platform The technology aims to help adults living with Type 1 or Type 2 diabetes and clinicians make informed, data-backed decisions. Gilead obtains FDA OK for new indication for Vemlidy Vemlidy is now approved for the treatment of chronic Hepatitis B virus infection in pediatric patients. Lupin to acquire 2 inhalation brands from Sunovion Lupin is acquiring Brovana inhalation solution and Xopenex HFA inhalation aerosol from Sunovion for $75 million. FDA OKs new indication for Janssen's Tecvayli Tecvayli, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options. Lannett obtains FDA nod to manufacture Numbrino in Indiana The approval allows Lannett’s site in Seymour, Ind. to rapidly expand liquid drug manufacturing. Tris Pharma supplying Dyanavel XR amid Adderall shortage Dyanavel XR is FDA-approved for the treatment of Attention-Deficit Hyperactivity Disorder in patients aged 6 years old and older. Amylyx obtains FDA nod for Relyvrio Relyvrio is a treatment option for patients with ALS, commonly referred to as Lou Gehrig’s disease. Bristol Myers Squibb obtains FDA nod for Sotyktu Sotyktu is an oral treatment for adults with moderate-to-severe plaque psoriasis. First Previous 9 10 11 12 13 Next Last
